Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Communications • Semiconductors, Circuits & Optics • Medical Devices & Mechanical Engineering
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Kowa Company, Ltd. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners and 4 distinct art units. This shows that each of the 5 pending actions is being handled by a different examiner, with almost every action residing in a different technical group.
ROSENTHAL, ANDREW S is the busiest examiner for the company, with 1 pending office action. The spread across 4 art units for 5 actions indicates that the company's pharmaceutical filings are being reviewed by multiple specialized technical groups. For a practitioner, this suggests that the company's innovations in Biotechnology & Pharmaceuticals are technically diverse. With 5 distinct examiners involved, the prosecution experience is highly decentralized, meaning that the outcome of each application is independent of the others. This requires a flexible strategy that can address the specific standards of 4 different art units while managing the individual requirements of 5 different examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §103 only | 2 (29%) |
| §102 only | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
| KENYON, JOHN S | 1 | 79.7% | +18.3% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| DRAPER, LESLIE A ROYDS | 1 | 27.3% | +43.4% |
| APENTENG, JESSICA MCMILLAN | 1 | 65.4% | +18.8% |
| MANDEVILLE, JASON M | 1 | 55.4% | +46.1% |
| PATEL, NIDHI NIRAJ | 1 | 53.8% | +46.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | DRAPER, LESLIE A ROYDS | 14d |
| 19101601 | POLYMER CONTRAST AGENT | ROSENTHAL, ANDREW S | — |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | ROZOF, TIMOTHY R | — |
| 18008486 | METHOD FOR ESTIMATING FLUID STATE OF LIQUID, AND SYSTEM FOR ESTIMATING FLUID STATE OF LIQUID | PATEL, NIDHI NIRAJ | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287210 | RING-TYPE LIGHTING DEVICE | APENTENG, JESSICA MCMILLAN | 4d overdue |
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | DRAPER, LESLIE A ROYDS | 14d |
| 19101601 | POLYMER CONTRAST AGENT | ROSENTHAL, ANDREW S | — |
| 18880136 | DRUG FOR LOWERING BLOOD LDL CHOLESTEROL | KENYON, JOHN S | — |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | ROZOF, TIMOTHY R | — |
| 18043282 | MEDICAL EXAMINATION DEVICE | MANDEVILLE, JASON M | — |
| 18008486 | METHOD FOR ESTIMATING FLUID STATE OF LIQUID, AND SYSTEM FOR ESTIMATING FLUID STATE OF LIQUID | PATEL, NIDHI NIRAJ | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 2875 | 1 |
| 2623 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19101601 | POLYMER CONTRAST AGENT | ROSENTHAL, ANDREW S | — | §102§112Other | Non-Final OA | — | Pending | Feb 06, 2025 |
| 18880136 | DRUG FOR LOWERING BLOOD LDL CHOLESTEROL | KENYON, JOHN S | — | §102 | Non-Final OA | — | Pending | Dec 30, 2024 |
| 18849005 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE | ROZOF, TIMOTHY R | — | §101§102§103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18605928 | THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE | DRAPER, LESLIE A ROYDS | 1629 | §102§112Other | Non-Final OA | 14d | Pending | Mar 15, 2024 |
| 18287210 | RING-TYPE LIGHTING DEVICE | APENTENG, JESSICA MCMILLAN | 2875 | §103 | Non-Final OA | 4d overdue | Pending | Oct 17, 2023 |
| 18043282 | MEDICAL EXAMINATION DEVICE | MANDEVILLE, JASON M | 2623 | §103 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18008486 | METHOD FOR ESTIMATING FLUID STATE OF LIQUID, AND SYSTEM FOR ESTIMATING FLUID STATE OF LIQUID | PATEL, NIDHI NIRAJ | 3791 | §101§103 | Final Rejection | — | Pending | Dec 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial